1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

Deadly COVID-19 Hand Sanitizer Production Surge Prompted US FDA's New Import Alert Category

 
• By Joanne S. Eglovitch

New import alert category and border testing required after reduced standards put dangerous sanitizers into hands of US consumers.

Coronavirus prevention medical surgical masks and hand sanitizer gel for hand hygiene corona virus protection.
US FDA Creates New Import Category In Responding To Loosening Manufacturing Standards • Source: Shutterstock

The US Food and Drug Administration has created a new import alert category, 66-78, to stem the importation of contaminated hand sanitizers, which has caused nationwide adverse events and some deaths.

The agency's action responds to methanol contamination that followed a loosening standards for these products to enable a swift increase in production to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Compliance

Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

Aragen’s CEO Says NIH Funding Cut Means Less R&D Money, And Tariffs Would Add To Woes

 
• By Vibha Ravi

Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an audio interview.